title: Three-year follow-up after rotational atherectomy for the treatment of diffuse in-stent restenosis: predictors of major adverse cardiac events.
abstract: Restenosis remains the major limitation of coronary stent implantation, especially in diffuse forms of in-stent restenosis. In this study, rotablation (RA) with adjunct angioplasty of in-stent restenosis was performed in 84 patients. Clinical follow-up and control angiography were obtained 6-month postprocedure. The rate of recurrent restenosis after rotablation for in-stent restenosis at 6-month angiographic follow-up was 45%, resulting in a rate of major adverse cardiac events of 35%. At 3-year follow-up, the cumulative event-free survival rate was 57% for the entire population. The only predictor of MACE at 3-year clinical follow-up by multivariate logistic regression analysis was in-stent lesion length. RA for the treatment of diffuse in-stent restenosis is thereby characterized by high procedural success rates and recurrent angiographic restenosis in 45% of patients with diffuse lesions. Major adverse cardiac events occur most likely within the first 6 months postprocedure. Three years after rotablation of in-stent restenosis, 43% of patients had experienced at least one major adverse cardiac event. Cathet Cardiovasc Intervent 2001;53:334-340.
authors.affiliation: Medical Clinic I, University Hospital Aachen, Aachen, Germany. p.radke@ic.ac.uk
authors.forename: P W
authors.initials: PW
authors.lastname: Radke
authors.forename: J
authors.initials: J
authors.lastname: vom Dahl
authors.forename: R
authors.initials: R
authors.lastname: Hoffmann
authors.forename: H G
authors.initials: HG
authors.lastname: Klues
authors.forename: M
authors.initials: M
authors.lastname: Hosseini
authors.forename: U
authors.initials: U
authors.lastname: Janssens
authors.forename: P
authors.initials: P
authors.lastname: Hanrath
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000401:mortality; D017225:Atherectomy, Coronary / Q000009:adverse effects* / Q000401:mortality; D003131:Combined Modality Therapy / Q000009:adverse effects; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000000981:diagnostic imaging / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000209:etiology*; D009204:Myocardial Revascularization; D011237:Predictive Value of Tests; D012008:Recurrence; D015607:Stents / Q000009:adverse effects; D013997:Time Factors; D014463:Ultrasonography